362 related articles for article (PubMed ID: 9180298)
21. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
Ozerol I; Ageitos A; Heimann DG; Talmadge JE
Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
[TBL] [Abstract][Full Text] [Related]
22. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
[TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
26. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
[TBL] [Abstract][Full Text] [Related]
28. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi ML; Castelli C; Orazi A; Polli N; Bregni M; Siena S
Br J Haematol; 1991 Jun; 78(2):197-205. PubMed ID: 2064957
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft.
Komatsu F; Kajiwara M
Jpn J Cancer Res; 1996 Feb; 87(2):161-9. PubMed ID: 8609065
[TBL] [Abstract][Full Text] [Related]
30. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
Charak BS; Malloy B; Agah R; Mazumder A
Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
[TBL] [Abstract][Full Text] [Related]
31. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
32. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
[TBL] [Abstract][Full Text] [Related]
33. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
34. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
[TBL] [Abstract][Full Text] [Related]
35. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
36. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
38. Effect of heat-pretreatment on interleukin-2-activated killer cells for in vitro purging.
Tanaka M; Honda J; Imamura Y; Shiraishi K; Tanaka K; Oizumi K
Pathobiology; 2000; 68(3):124-8. PubMed ID: 11174069
[TBL] [Abstract][Full Text] [Related]
39. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
40. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]